Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.276,82
0,62%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Biohaven Ltd (BHVN) Biohaven Ltd (BHVN) Notizie

Biohaven Ltd

BHVN
40,69
0,79 (1,98%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
22/4/202422:05PRNUSBiohaven Announces Closing of Public Offering and Full..
17/4/202422:05PRNUSBiohaven Announces Proposed Public Offering of Common Shares
13/4/202415:00PRNUSBiohaven Showcases Innovative Neuroscience Portfolio with 20..
29/2/202422:16EDGAR2Form 8-K - Current report
29/2/202422:05PRNUSBiohaven Reports Fourth Quarter and Full Year 2023 Financial..
08/1/202413:30EDGAR2Form 8-K - Current report
08/1/202413:30PRNUSBiohaven Highlights Progress Across Innovative Portfolio and..
02/1/202413:00PRNUSBiohaven to Present at the 42nd Annual J.P. Morgan..
01/12/202322:30PRNUSBiohaven Presents Expanded EEG and Safety Data for BHV-7000..
14/11/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202322:05PRNUSBiohaven Reports Third Quarter 2023 Financial Results and..
16/10/202313:00PRNUSBiohaven Presents Preclinical Data Demonstrating..
05/10/202322:05EDGAR2Form 8-K - Current report
05/10/202322:05PRNUSBiohaven Announces Closing of Public Offering and Full..
04/10/202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/10/202305:56PRNUSBiohaven Announces Pricing of $225 Million Public Offering..
03/10/202303:41EDGAR2Form 8-K - Current report
02/10/202323:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202323:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202322:36PRNUSBIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
02/10/202322:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
27/9/202312:58EDGAR2Form 8-K - Current report
14/9/202313:00PRNUSBiohaven Completes Enrollment in Pivotal Phase 3 Study of..
05/9/202313:00PRNUSBiohaven Announces Positive Data from its Exploratory..
31/7/202323:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/7/202322:29EDGAR2Form 8-K - Current report
31/7/202315:31PRNUSBiohaven's Taldefgrobep Alfa Receives EU Orphan Drug..
31/7/202312:59PRNUSBiohaven Reports Second Quarter 2023 Financial Results and..
28/7/202322:35EDGAR2Form 8-K - Current report
27/7/202314:42DJNBiohaven Told That FDA Won't Review NDA Application for..
27/7/202313:00PRNUSBiohaven Provides Preliminary EEG Data Update for Kv7..
31/5/202313:00PRNUSBiohaven Provides Overview of Clinical Progress, Regulatory..
25/5/202323:00PRNUSBiohaven to Present R&D Day at Yale School of Management
12/5/202322:30PRNUSBiohaven Reports First Quarter 2023 Financial Results and..
Apertura: 40,72 Min: 40,45 Max: 42,105
Chiusura: 39,90

La tua Cronologia

NYSE
BHVN
Biohaven
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network